Claims

1. The use of nabumetone in the manufacture of a medicament for the treatment of myofascial pain syndrome.

5

2. A use according to claim 1 wherein the medicament is adapted for oral administration.

3. A use according to claim 1 wherein the medicament is 10 adapted for parenteral administration.

. A use according to claim 1 wherein the medicament is adapted for topical administration.

155. A use according to any one of claims 1 to 4 wherein the medicament is in unit dose form and contains from 20 to 2000 mg of nabumetone.

6. A use according to claim 1 or 2 wherein the medicament 0 is in the form of a swallow tablet containing 500 mg or 1000 mg of nabumetone.

7. A method for the treatment of MPS in human or non- human animals, which comprises administering an effective, 5 non-toxic amount of nabumetone to a sufferer in need thereof.

8. A method according to claim 7 wherein the nabumetone is in a form adapted for oral administration. 0

9. A method according to claim 7 wherein the nabumetone is in a form adapted for parenteral administration..

10. A method according to claim 7 wherein the nabumetone 5 is in a form adapted for topical administration.

11. A method according to claim 7 wherein the nabumetone is in unit dose composition containing from 20 to 2000 mg of nabumetone.

512. A method according to claim 7 wherein the nabumetone is in the form of a swallow tablet composition containing 500 mg or 1000 mg of nabumetone.

13. A pharmaceutical composition for use in the treatment 0 of MPS which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 which is adapted for oral administration. 5

15. A pharmaceutical composition according to claim 13 which is adapted for parenteral administration.

16. A pharmaceutical composition according to claim 13 0 which is adapted for topical administration.

17. A pharmaceutical composition according to claim 13 wherein the nabumetone is in unit dose composition containing from 20 to 2000 mg. 5

18. A pharmaceutical composition according to claim 13 wherein the nabumetone is in the form of a swallow tablet composition containing 500 mg or 1000 mg of nabumetone.